Streptococcus pneumoniae is a bacterium with genetic variability: there are over 100 serotypes, some of which are associated with particularly severe infections.
Young children below the age of five years and children above 65 years of age are most vulnerable to these infections. Photo: Shutterstock.
Researchers from various fields at the Carlos III Health Institute (ISCIII) and the Network Biomedical Research Center Consortium (CIBER) have developed a new model to study bacteria that cause diseases such as pneumoniae You Meningitis,
This is thanks to the creation of pulmonary organoids, or mini-lungs, created in the laboratory through the use of embryonic pluripotent stem cells, which mimic real lung activity.
,Streptococcus pneumoniae‘ O pneumococcusa bacterium that is capable of developing something minor ailmentssuch as otitis or sinusitis, but which in turn allows the development of more serious ones such as pneumoniae, Meningitis You sepsis,
“These small lungs reproduce the structure and function of the parent organ relatively well and serve to model any human respiratory disease, facilitating the discovery of new targets of therapeutic interest and the testing of new compounds.” provides”, confirms Alberto Zambrano from the Biotechnology Laboratory. of stem cells and organoids from UFIEC.
Young children below the age of five years and children above 65 years of age are most vulnerable to these infections.
Currently, medicine has vaccines that protect patients from the most frequent serotypes, but since it is a bacterium with high genetic variability, and having more than 100 serotypes, few appear to be resistant to antibiotics. are resistant, and similarly, cases in which the vaccine would have no effect and could pose a public health threat are on the rise.
The study model based on small lungs allows us to analyze how the lung behaves. pneumococcus In these prostheses, allowing researchers to better understand their behavior as they infect the actual lungs, and what they cause over time.
“We can study the virulence mechanisms of various respiratory pathogens and characterize the activity of new antimicrobial drugs against bacteria that are multiresistant to antibiotics,” concludes José Yust, head of the CNM-ISCIII pneumococcal reference laboratory. .
Source consulted here.